{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-344787","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2026-08-11T20:30:18+00:00","discovered_at":"2026-08-11T20:31:00.554614+00:00","generated_at":"2026-08-11T20:31:10.047118+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVITA Medical amends PermeaDerm agreements: higher revenue share, EU/UK/AU expansion option","bullets":["$500,000 fee gives AVITA right of first offer/refusal to expand exclusive PermeaDerm distribution to EU, UK, Australia.","Revenue share from PermeaDerm rises to 67% (sheet) and 80% (glove) from July 1, 2026; extra payments if gross margin >50% (sheet) or >35% (glove).","Growth minimums set: $1.0M in 2026, then 20% annual growth to $2.0736M by 2030; prior minimums waived.","Stedical can sell in certain U.S. markets; AVITA supplies at cost +10%. For OUS (Asia) sales, price $200/carton + 10% manufacturing fee up to 1,600 cartons.","Milestone payments: AVITA pays $1M if total sales exceed $45M, and $1.5M if exceed $90M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-344787","json":"https://secwatch.observer/filing/0001193125-26-344787.json","markdown":"https://secwatch.observer/filing/0001193125-26-344787.md","text":"https://secwatch.observer/filing/0001193125-26-344787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526344787/0001193125-26-344787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312526344787/rcel-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T20:31:10.047118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}